Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ADBPO is a topical combination gel developed and marketed by VTS Life Sciences for the treatment of moderate to severe acne vulgaris. It contains two active ingredients: adapalene (0.1% w/w), a third-generation retinoid, and benzoyl peroxide (2.5% w/w), an oxidizing agent with antibacterial and keratolytic properties. Adapalene works by modulating cellular differentiation and keratinization to prevent the formation of comedones, while benzoyl peroxide provides bactericidal activity against *Cutibacterium acnes* and helps exfoliate the skin by breaking down keratin. This synergistic combination targets multiple pathways of acne pathogenesis, including follicular hyperkeratosis and bacterial proliferation, and is typically used to reduce acne lesions such as pimples, whiteheads, and blackheads.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ADBPO.